JACC:年轻Brugada综合征患者的临床特征研究

2019-04-19 不详 MedSci原创

年轻Brugada综合征(BrS)患者的临床特征和预后尚不清楚。本研究的目的旨在评估年轻BrS患者的临床特征、治疗管理和心律不齐事件(AEs)的危险因素。 本研究纳入了57例年龄<20岁的BrS患者,并分为儿童组(年龄≤12岁,n=26),和青少年组(年龄13-20岁,n=31)。结果分析显示,患者第一次发生心律不齐事件的平均年龄为14岁,男性占多数(74%),部分患者(28%)表现为发

年轻Brugada综合征(BrS)患者的临床特征和预后尚不清楚。本研究的目的旨在评估年轻BrS患者的临床特征、治疗管理和心律不齐事件(AEs)的危险因素。

 

本研究纳入了57例年龄<20岁的BrS患者,并分为儿童组(年龄≤12岁,n=26),和青少年组(年龄13-20岁,n=31)。结果分析显示,患者第一次发生心律不齐事件的平均年龄为14岁,男性占多数(74%),部分患者(28%)表现为发热相关的AEs,分别有26%, 49%, 65%, 28%58%的患者有心源性猝死家族史、晕厥史、自发性1Brugada心电图、诱发性室颤和SCN5A基因突变。相比于青少年组,儿童组的女性、白种人、发热相关AE和自发性1Brugada心电图者更多。在随访期间,有68%的儿童组和64%的青少年组有反复性AE,近三分之一反复性AE是在奎尼丁治疗后,儿童组60%的反复性AE与发热相关。反复性AE的风险因素包括窦房结功能障碍、房性心律失常、心室内传导阻滞或1导联的宽大S波。

 

研究结果显示,年轻Brugada综合征患者的心律失常较常见,且易复发。


原始出处:

Yoav M et al.Characterization and Management of Arrhythmic Events in Young Patients With Brugada Syndrome.JACC.2019 Apr.


本文系梅斯医学(MedSci)原创编译整理,转载需授权

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2081242, encodeId=a09620812421a, content=<a href='/topic/show?id=e1ab3e481d' target=_blank style='color:#2F92EE;'>#Brugad#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3748, encryptionId=e1ab3e481d, topicName=Brugad)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sun Mar 08 22:42:00 CST 2020, time=2020-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1842895, encodeId=914f184289572, content=<a href='/topic/show?id=112222886b8' target=_blank style='color:#2F92EE;'>#临床特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22886, encryptionId=112222886b8, topicName=临床特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Sun Jan 19 05:42:00 CST 2020, time=2020-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854362, encodeId=e800185436222, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Aug 19 01:42:00 CST 2019, time=2019-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264694, encodeId=88521264694a7, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Sun Apr 21 00:42:00 CST 2019, time=2019-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326183, encodeId=99421326183be, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun Apr 21 00:42:00 CST 2019, time=2019-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431492, encodeId=c578143149259, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sun Apr 21 00:42:00 CST 2019, time=2019-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590755, encodeId=ce801590e55d0, content=<a href='/topic/show?id=86e23e49d6' target=_blank style='color:#2F92EE;'>#Brugada#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3749, encryptionId=86e23e49d6, topicName=Brugada)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=939917859602, createdName=nymo, createdTime=Sun Apr 21 00:42:00 CST 2019, time=2019-04-21, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2081242, encodeId=a09620812421a, content=<a href='/topic/show?id=e1ab3e481d' target=_blank style='color:#2F92EE;'>#Brugad#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3748, encryptionId=e1ab3e481d, topicName=Brugad)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sun Mar 08 22:42:00 CST 2020, time=2020-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1842895, encodeId=914f184289572, content=<a href='/topic/show?id=112222886b8' target=_blank style='color:#2F92EE;'>#临床特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22886, encryptionId=112222886b8, topicName=临床特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Sun Jan 19 05:42:00 CST 2020, time=2020-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854362, encodeId=e800185436222, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Aug 19 01:42:00 CST 2019, time=2019-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264694, encodeId=88521264694a7, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Sun Apr 21 00:42:00 CST 2019, time=2019-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326183, encodeId=99421326183be, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun Apr 21 00:42:00 CST 2019, time=2019-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431492, encodeId=c578143149259, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sun Apr 21 00:42:00 CST 2019, time=2019-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590755, encodeId=ce801590e55d0, content=<a href='/topic/show?id=86e23e49d6' target=_blank style='color:#2F92EE;'>#Brugada#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3749, encryptionId=86e23e49d6, topicName=Brugada)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=939917859602, createdName=nymo, createdTime=Sun Apr 21 00:42:00 CST 2019, time=2019-04-21, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2081242, encodeId=a09620812421a, content=<a href='/topic/show?id=e1ab3e481d' target=_blank style='color:#2F92EE;'>#Brugad#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3748, encryptionId=e1ab3e481d, topicName=Brugad)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sun Mar 08 22:42:00 CST 2020, time=2020-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1842895, encodeId=914f184289572, content=<a href='/topic/show?id=112222886b8' target=_blank style='color:#2F92EE;'>#临床特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22886, encryptionId=112222886b8, topicName=临床特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Sun Jan 19 05:42:00 CST 2020, time=2020-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854362, encodeId=e800185436222, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Aug 19 01:42:00 CST 2019, time=2019-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264694, encodeId=88521264694a7, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Sun Apr 21 00:42:00 CST 2019, time=2019-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326183, encodeId=99421326183be, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun Apr 21 00:42:00 CST 2019, time=2019-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431492, encodeId=c578143149259, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sun Apr 21 00:42:00 CST 2019, time=2019-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590755, encodeId=ce801590e55d0, content=<a href='/topic/show?id=86e23e49d6' target=_blank style='color:#2F92EE;'>#Brugada#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3749, encryptionId=86e23e49d6, topicName=Brugada)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=939917859602, createdName=nymo, createdTime=Sun Apr 21 00:42:00 CST 2019, time=2019-04-21, status=1, ipAttribution=)]
    2019-08-19 hbwxf
  4. [GetPortalCommentsPageByObjectIdResponse(id=2081242, encodeId=a09620812421a, content=<a href='/topic/show?id=e1ab3e481d' target=_blank style='color:#2F92EE;'>#Brugad#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3748, encryptionId=e1ab3e481d, topicName=Brugad)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sun Mar 08 22:42:00 CST 2020, time=2020-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1842895, encodeId=914f184289572, content=<a href='/topic/show?id=112222886b8' target=_blank style='color:#2F92EE;'>#临床特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22886, encryptionId=112222886b8, topicName=临床特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Sun Jan 19 05:42:00 CST 2020, time=2020-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854362, encodeId=e800185436222, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Aug 19 01:42:00 CST 2019, time=2019-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264694, encodeId=88521264694a7, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Sun Apr 21 00:42:00 CST 2019, time=2019-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326183, encodeId=99421326183be, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun Apr 21 00:42:00 CST 2019, time=2019-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431492, encodeId=c578143149259, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sun Apr 21 00:42:00 CST 2019, time=2019-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590755, encodeId=ce801590e55d0, content=<a href='/topic/show?id=86e23e49d6' target=_blank style='color:#2F92EE;'>#Brugada#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3749, encryptionId=86e23e49d6, topicName=Brugada)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=939917859602, createdName=nymo, createdTime=Sun Apr 21 00:42:00 CST 2019, time=2019-04-21, status=1, ipAttribution=)]
    2019-04-21 般若傻瓜
  5. [GetPortalCommentsPageByObjectIdResponse(id=2081242, encodeId=a09620812421a, content=<a href='/topic/show?id=e1ab3e481d' target=_blank style='color:#2F92EE;'>#Brugad#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3748, encryptionId=e1ab3e481d, topicName=Brugad)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sun Mar 08 22:42:00 CST 2020, time=2020-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1842895, encodeId=914f184289572, content=<a href='/topic/show?id=112222886b8' target=_blank style='color:#2F92EE;'>#临床特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22886, encryptionId=112222886b8, topicName=临床特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Sun Jan 19 05:42:00 CST 2020, time=2020-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854362, encodeId=e800185436222, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Aug 19 01:42:00 CST 2019, time=2019-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264694, encodeId=88521264694a7, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Sun Apr 21 00:42:00 CST 2019, time=2019-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326183, encodeId=99421326183be, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun Apr 21 00:42:00 CST 2019, time=2019-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431492, encodeId=c578143149259, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sun Apr 21 00:42:00 CST 2019, time=2019-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590755, encodeId=ce801590e55d0, content=<a href='/topic/show?id=86e23e49d6' target=_blank style='color:#2F92EE;'>#Brugada#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3749, encryptionId=86e23e49d6, topicName=Brugada)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=939917859602, createdName=nymo, createdTime=Sun Apr 21 00:42:00 CST 2019, time=2019-04-21, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2081242, encodeId=a09620812421a, content=<a href='/topic/show?id=e1ab3e481d' target=_blank style='color:#2F92EE;'>#Brugad#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3748, encryptionId=e1ab3e481d, topicName=Brugad)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sun Mar 08 22:42:00 CST 2020, time=2020-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1842895, encodeId=914f184289572, content=<a href='/topic/show?id=112222886b8' target=_blank style='color:#2F92EE;'>#临床特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22886, encryptionId=112222886b8, topicName=临床特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Sun Jan 19 05:42:00 CST 2020, time=2020-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854362, encodeId=e800185436222, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Aug 19 01:42:00 CST 2019, time=2019-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264694, encodeId=88521264694a7, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Sun Apr 21 00:42:00 CST 2019, time=2019-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326183, encodeId=99421326183be, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun Apr 21 00:42:00 CST 2019, time=2019-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431492, encodeId=c578143149259, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sun Apr 21 00:42:00 CST 2019, time=2019-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590755, encodeId=ce801590e55d0, content=<a href='/topic/show?id=86e23e49d6' target=_blank style='color:#2F92EE;'>#Brugada#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3749, encryptionId=86e23e49d6, topicName=Brugada)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=939917859602, createdName=nymo, createdTime=Sun Apr 21 00:42:00 CST 2019, time=2019-04-21, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2081242, encodeId=a09620812421a, content=<a href='/topic/show?id=e1ab3e481d' target=_blank style='color:#2F92EE;'>#Brugad#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3748, encryptionId=e1ab3e481d, topicName=Brugad)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sun Mar 08 22:42:00 CST 2020, time=2020-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1842895, encodeId=914f184289572, content=<a href='/topic/show?id=112222886b8' target=_blank style='color:#2F92EE;'>#临床特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22886, encryptionId=112222886b8, topicName=临床特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Sun Jan 19 05:42:00 CST 2020, time=2020-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854362, encodeId=e800185436222, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Aug 19 01:42:00 CST 2019, time=2019-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264694, encodeId=88521264694a7, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Sun Apr 21 00:42:00 CST 2019, time=2019-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326183, encodeId=99421326183be, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun Apr 21 00:42:00 CST 2019, time=2019-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431492, encodeId=c578143149259, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sun Apr 21 00:42:00 CST 2019, time=2019-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590755, encodeId=ce801590e55d0, content=<a href='/topic/show?id=86e23e49d6' target=_blank style='color:#2F92EE;'>#Brugada#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3749, encryptionId=86e23e49d6, topicName=Brugada)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=939917859602, createdName=nymo, createdTime=Sun Apr 21 00:42:00 CST 2019, time=2019-04-21, status=1, ipAttribution=)]
    2019-04-21 nymo

相关资讯

盘点:JACC四月第二期研究一览

1.非致密性心肌病家系的心脏表型和基因特征研究DOI: 10

JACC:慢性主动脉瓣反流患者的预后研究

目前,对明显主动脉瓣反流(AR)患者的特征和预后尚不清楚。本研究的目的旨在评估主动脉瓣修复或置换术(AVR)对AR患者的益处以及左室大小对AR患者预后的预测价值。本研究纳入了748例无心梗和心脏手术史的中重度慢性AR患者(平均年龄58±17岁,男性占82%),其中52%患者接受了治疗,48%患者接受了AVR治疗。在361名接受AVR治疗患者中,334名符合指南标准。经过平均4.9年时间的随访,12

JAHA:他汀类药物与糖尿病发生呈时间剂量相关性

他汀类药物被越来越广泛地用于一级预防,但是他汀药物与糖尿病发生的相关性问题不容忽视。本研究纳入了2005-2012年年龄≥40岁的复合他汀类药物适应症的高血脂患者,主要终点事件是接受药物治疗后的新发糖尿病。在2162119名复合他汀药物治疗适应症的高血脂患者中,有29.5%患者曾经使用过他汀类药物,经过平均3.9年时间的随访,相比于从没使用过他汀药物患者,使用过他汀药物患者的糖尿病风险明显更高(H

Circulation:2型糖尿病的诊断年龄与心血管和死亡风险的关联

由此可见,诊断T2DM的年龄对于生存和心血管风险具有重要的预后价值,对于确定临床决策和指导性治疗的危险因素干预的时间和强度具有重要意义。这些观察结局扩大了对年轻个体预防/延迟T2DM发作的支持力度。

JACC:标准化治疗可改善心源性休克预后

心源性休克(CS)是一种多因素的血流动力学复杂的综合征,死亡率高。尽管在再灌注和机械循环支持方面取得了进展,但CS的治疗方法仍然存在很大的差异,且效果不佳。本研究的目的旨在评估以团队为基础的标准化方法是否可以改善CS的预后。本研究纳入分析了204名CS患者,并对患者的CS病因、人口统计学特征、右心导管插入术、机械循环支持使用和生存率进行了统计,在基线水平和CS诊断后24小时测量了患者的心输出功率(

JACC:经导管主动脉瓣置换术后感染性心内膜炎的远期发生率研究

接受外科主动脉瓣置换术(SAVR)后的患者发生感染性心内膜炎(IE)的风险会更高,然而经导管主动脉瓣置换术(TAVR)后的IE发生风险尚不清楚。本研究纳入分析了丹麦国家数据库中的2632名接受TAVR治疗和3777名接受SAVR治疗的无IE病史的患者,经过平均3.6年时间的随访,4.4%的TAVR组患者和4.9%的SAVR组患者出现感染性心内膜炎,两组患者从手术到IE住院之间的平均时间间隔分别为3